From GlobeNewswire: 2025-03-18 16:05:00

Maravai LifeSciences Holdings, Inc. reported financial results for Q4 and full year 2024, with quarterly revenue at $56.6 million, net loss at $(46.1) million, and Adjusted EBITDA at $(1.1) million. Corporate updates include appointing R. Andrew Eckert as Chairman of the Board and prepaying $228 million of the Term Loan. Acquisitions and partnerships were completed to enhance capabilities and expand reach. The company plans to provide financial guidance for 2025 on March 20, 2025.

For Q4 2024, revenue was $56.6 million, a 23.7% decrease from the same period in 2023. Nucleic Acid Production revenue was $41.9 million, down 28.8%, and Biologics Safety Testing revenue was $14.7 million, a 4.3% decrease year-over-year. Net loss and Adjusted EBITDA were $(46.1) million and $(1.1) million, respectively.

For the full year 2024, revenue was $259.2 million, a 10.3% decrease from the prior year. Nucleic Acid Production revenue was $196.3 million, down 12.6%, and Biologics Safety Testing revenue was $62.8 million, a 2.1% decrease year-over-year. Net loss and Adjusted EBITDA were $(259.6) million and $35.9 million, respectively.

Maravai’s CEO, Trey Martin, expressed a focus on executing the return-to-growth strategy through differentiated technologies. Non-GAAP financial measures like Adjusted EBITDA and Adjusted Net (Loss) Income provide a more comprehensive view of the company’s performance. Maravai LifeSciences aims to support drug therapies, diagnostics, and research with critical products and services.

Forward-looking statements caution investors that future performance may differ from expectations. Factors impacting Maravai’s results include customer spending, market stability, competition, regulatory changes, and cybersecurity risks. The company’s financial health, acquisitions, and potential tax liabilities are also key considerations for investors. Management emphasizes adherence to GAAP while using non-GAAP measures for supplementary analysis.



Read more at GlobeNewswire:: Maravai Lifesciences Reports Fourth Quarter and Full Year